Trump Administration Signals Deference To Congress On Drug Pricing Policy

 
• By Cathy Kelly

In a marked departure from previous years, budget proposal offers few specifics on cost reductions, but the $135bn savings estimate is a tacit endorsement of the Grassley-Wyden bill in the Senate.

Man on a mountain peak looking through binoculars to a red flag. The concept of reaching goals.
We're A Long Way From There

More from Pricing Debate

More from Market Access